Research Article

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

www.irjponline.com

ISSN 2230-8407 [LINKING]

ASSESSMENT AND EFFECTS OF IPPA AND ITS DESIGNS ON PEOPLE WITH ULCERATIVE COLITIS AND CONCOMITANT PSC, AS WELL AS THE INCIDENCE OF NEOPLASIA IN IPAA PARTICIPANTS AND THE RESULTS OF IRA AND IPAA

Dr. Sanjay Kumar Singh

Assistant Professor, Department of General Surgery, Icare Institute of Medical Sciences and Research & Dr. Bidhan Chandra Roy Hospital, Haldia, West bengal

Address for correspondence

Email: drsanjaysingh959@gmail.com

Singh SK. Surgical Therapy Of The Haemorrhoids: A Comparison Between Stapled And Traditional Hemorrhoidectomy. International Research Journal Of Pharmacy 2019,10:11:80-84.

DOI: 10.7897/2230-8407.1011323

==========

ABSTRACT

Background: One of the most recommended treatments for ulcerative colitis is IPAA. It is, nonetheless, linked to a number of difficulties, some of which may manifest early on. These early problems, which occur in 30–50% of patients, are similar to those observed in abdominal procedures. Following IPAA surgery, late problems might appear more than 90 days later.

Aim: The purpose of the current clinical investigation was to assess the effects of IPPA and its designs on people with ulcerative colitis and concomitant PSC, as well as the incidence of neoplasia in IPAA participants and the results of IRA and IPAA.

Methods: 186 participants' demographics, medical histories, physical examinations, diagnoses, surgeries, functional results, histology, related problems, and failures were recorded. Recorded were the Pouchitis, Proctitis, Endoscopy, and Pouch Functional Score. Evaluations of complications after IPAA or IRA were also conducted. The gathered information was statistically assessed, and conclusions were drawn.

Results: Bowel movement throughout the day was graded as 0, 1, and 2 in 28.94% (n=11), 50% (n=19), and 15.78% (n=6) participants with UC and in 28.57% (n=2), 0, and 71.42% (n=5) subjects with UC and PSC, respectively, after receiving IPAA therapy. Of the participants with UC and PSC, 12.5% (n=2) had pouchitis-related failure. In 12.90% (n=4) of the participants with UC alone and 62.5% (n=10) of the subjects with UC plus PSC, there were more than four episodes of pouchitis.

Conclusion: K-pouch with stapled anastomosing had the greatest long-term functional results in patients with ulcerative colitis and had a very low incidence of neoplasia after treatment. Subjects receiving IRA treatment for PSC and UC had high failure rates and reduced functional results. Nonetheless, IPAA demonstrated similar results in those with UC alone or UC combined with PSC.

Keywords: Primary sclerosing cholangitis ulcerative colitis complications IPAA IRA neoplasia

INTRODUCTION

Relapsing ulcerative colitis is an inflammatory illness of the large intestine. Young subjects are primarily affected by ulcerative colitis. Nonetheless, persons of any age may be impacted. Numerous non-genetic and genetic variables interact to create ulcerative colitis. When individuals are genetically susceptible to bacteria found in the intestinal lumen, the aberrant inflammatory response is the pathophysiology of ulcerative colitis. Moreover, there are genetic similarities between Crohn's disease and ulcerative colitis. However, the pathophysiology of ulcerative colitis is also influenced by non-genetic factors.[1]

In the gut, mucosal cells serve as a barrier against microbial invasion and as signalling agents. In ulcerative colitis, disruptions to the mucosal layer and junction between mucosal cells throw off the balance between these two roles. Bacterial translocation may result in an inflammatory response that damages local defences by eroding

epithelium and causing ulcerations. The first line of treatment for ulcerative colitis is medical pharmacologic control, which includes corticosteroids, 5-ASA, immunomodulators, and anti-TNF medications.2.

Treatment with pharmaceuticals works well for ulcerative colitis. Nevertheless, around 30% of patients with ulcerative colitis require surgical therapy because they are either refractory or have colon neoplasia. Additionally, it's required in life-threatening situations including toxic megacolon, refractory bleeding, and/or perforation. Considerations include quality of life relating to health, financial concerns, danger of pouchitis/proctitis, reproduction, failure rates, and problems following surgery. The most common surgical method is the abdominal colectomy, which can be done with or without an ileostomy.3 Surgery, such as ileal pouch-anal anastomosis (IPAA), proctectomy, ileostomy, continent ileostomy (Kock pouch), or ileorectal anastomosis (IRA), is performed with the intention of restoring bowel continuity. Segmental colon resection results in better functional outcomes. It is necessary to create anastomosis, which can be done using a stapler or by hand stitching.

One of the most recommended treatments for ulcerative colitis is IPAA. It is, nonetheless, linked to a number of difficulties, some of which may manifest early on.4 These early problems, which occur in 30–50% of patients, are similar to those observed in abdominal procedures. These include intestinal blockage, pelvic abscess, ileoanal anastomosis stenosis, anastomosing leak, and/or bleeding. These are manageable, but if they are not fixed, they may damage long-term functionality. Following IPAA surgery, late problems might appear more than 90 days later. These comprise pelvic fistulas, stricture of the ileoanal anastomosis, pouch failure, pouchitis, intestinal blockage, pouch vaginal haemorrhage, PSC (Primary sclerosing cholangitis), and/or pelvic sepsis (septic complications).5

With varying degrees of effectiveness, these late problems can also be surgically rectified. The goal of the current clinical investigation was to assess the effects of IPPA and its designs on people with ulcerative colitis and concomitant PSC, as well as the incidence of neoplasia in IPAA participants and the results of IRA and IPAA.

MATERIALS AND METHODS

In order to assess the effects of IPPA and its designs on long-term functioning, neoplasia frequency in IPAA individuals, and IRA and IPAA outcomes in people with ulcerative colitis and concomitant PSC, the current clinical retrospective investigation was carried out. The current investigation was carried out in the Department of General Surgery with approval from the relevant Ethics Committee. The data acquired from the IPAA-managed Department of Surgery at the Institute of subjects made up the research population. Complete records of patients treated by IPAA for ulcerative colitis or ulcerative colitis coexisting with primary sclerosing cholangitis (PSC) were required for inclusion. The IPAA participants' inadequate medical data served as the exclusion criterion. The subject's demographics, medical history, general physical examination, diagnosis, conducted surgery, functional results, histology, related complications, and failure were all taken from the patient's medical records.

A total of 186 patients of both sexes who were hospitalised to the surgery or gastroenterology department participated in the research. A validated questionnaire, together with the VAS (Visual Analogue Scale) and HRQoL (Health-Related Quality of Life), was used to measure pouch function. The Pouch Functional Score and the Oresland Score, which evaluates medication usage, urgency, and incontinence grade, were used to evaluate rectal functioning. Moreover, dietary limitations, perianal pain, challenges with evacuation, antibiotic use, and stool consistency.

Gastroscopes were used for endoscopy, and mucosal biopsies were performed. A single examiner with specialised knowledge evaluated the mucosa for ulcerations, lesions, polyps, edoema, loss of vascularity, granularity, and friability. We evaluated the anal transition zone samples for inflammation and dysplasia.The research participants' level of pouchitis was evaluated using the PDAI (Pouchitis Disease Activity Index), which rated histologic alterations, endoscopic findings, and clinical symptoms on a 0–6 scale for each criterion. In contrast, the Heidelberg score measured inflammation and changes related to inflammation. Proctitis was noted during the endoscopic follow-up. Histopathologically, inflammation was categorised as mild, moderate, severe, or absent.

When surgical or endoscopic care was required, complications that resulted from IPAA or IRA were taken into account. The following complications were evaluated in this study: haemorrhage, anastomotic stricture, pelvic sepsis, fistula, small intestinal obstruction, and anastomotic dehiscence. The Clavein-Dindo grading system, which categorises problems into four categories—anesthesia, failure, life-threatening complications, and death—was used to record the complications. Failure of IPAA was defined as pouch excision or diversion with proximal stroma lasting more than a year, whereas failure of IRA was defined as diversion or proctectomy lasting more than a year. The cause of the failure was also mentioned. Using SPSS software version 21 (Chicago, IL, USA) for statistical assessment and one-way ANOVA and t-test for result formulation, the gathered data were examined. The data were presented as a mean, standard deviation, percentage, and number. At $p<0.05$, the significance threshold was maintained.

RESULTS

In order to assess the effects of IPPA and its designs on long-term functioning, neoplasia frequency in IPAA individuals, and IRA and IPAA outcomes in people with ulcerative colitis and concomitant PSC, the current

clinical retrospective investigation was carried out. A total of 186 patients of both sexes who were hospitalised to the surgery or gastroenterology department participated in the research. The study's mean duration of follow-up was 1.68±1.12 years. The study's findings demonstrated a statistically significant ($p<0.005$) difference between the K- and J-pouch, with the pouch's design and surgical age serving as solid indicators of the Oresland score.

The instances with stapled J-pouch had the highest functional ratings, followed by handsewn J-pouch, handsewn K-pouch, and least with stapled K-pouch. The J-pouch group had greater rates of retarding drug usage, protective pad use, and difficulty with evacuation. One pathologist out of the two examiners in the IPAA for neoplasia observed low grade dysplasia in the pouch in one of the individuals.

The research participants showed no signs of high-grade dysplasia or cancer. Acute inflammation was observed to be present in 20.96% (n=39) and 24.73% (n=46) of the subjects, respectively, according to Examiners 1 and 2. Grade 3 was observed in 75.80% (n=141) and 51.07% (n=95) of the subjects, respectively, by Examiners 1 and 2, and Grade 4 in 79.03% (n=147) and 59.13% (n=110) of the subjects, respectively. Examiner 2 observed Grades 1, 2, and 3 for chronic inflammation in 4.83% (n = 9) of the participants, whereas Examiners 1 and 2 saw Grades 25.80% (n = 48) and 23.11% (n = 43) and 53.76% (n = 100) and 73.11% (n = 136) of the subjects, respectively.

Examiner 1 observed mucosal adaptation in 25.80% (n=48), 5.91% (n=11), and 58.06% (n=108) of the individuals, respectively, for Grades 1, 2, and 3. Grades 1, 2, and 3 were seen in 3.76% (n = 7), 18.81% (n = 35), and 48.92% (n = 91) of the patients in the ATZ region, respectively (Table 1).

There was no difference observed in participants receiving IPAA treatment who had primary sclerosing cholangitis concomitant with ulcerative colitis or who had ulcerative colitis alone. However, those with ulcerative colitis alone were more likely to receive a score of 8 or above. Individuals in the IRA group who also had primary sclerosing cholangitis and concomitant ulcerative colitis scored lower.

5.26% (n=2) of the individuals with UC and 28.57% (n=2) of the participants with UC with PSC had social impairment. In participants with UC, urgency was 42.85% (n=3) and 2.63% (n=1), respectively, with PSC. In 50% (n=19), 31.57% (n=12), and 13.15% (n=5) of the patients with UC, and in 0, 28.57% (n=2), and 57.14% (n=4) of the participants with UC with PSC, respectively, bowel movement occurred during the night. In 28.94% (n=11), 50% (n=19), and 15.78% (n=6) of the individuals with UC, respectively, bowel movement throughout the day was evaluated as 0, 1, and 2; in 28.57% (n=2), 0, and 71.42% (n=5) of the participants with UC and PSC, respectively (Table 2).

It was observed that, in comparison to people with UC alone, a considerably higher number of subjects with UC and PSC had pouchitis. Pouchitis was observed early in UC with PSC individuals. Of the participants with UC and PSC, 12.5% (n=2) had pouchitis-related failure. In 12.90% (n=4) of the participants with UC alone and 62.5% (n=10) of the subjects with UC plus PSC, there were more than four episodes of pouchitis. Of the subjects with pouchitis, 32.25% (n = 10) had UC by itself, and 81.25% (n = 13) had UC in conjunction with PSC.

As seen in Table 3, the first episode of pouchitis within a year following surgery was observed in 29.03% (n = 9) of participants with ulcerative colitis alone and in 62.5% (n = 10) of subjects with UC and concomitant PSC. In individuals with either UC alone or UC with PSC, proctitis did not demonstrate any importance.

After evaluating the surgical complications, it was discovered that there was no discernible difference between the participants who had IPAA or IRA treatment who either had ulcerative colitis only or together with primary sclerosing cholangitis. In terms of failure, it was seen that, in a statistically non-significant manner, the participants receiving IPAA, those receiving UC plus PSC, and those receiving UC alone had failure rates of 15% and 5%, respectively. On the other hand, failure rates for participants receiving IRA treatment were 21% and 52% for UC alone and UC with PSC, respectively. There was statistical significance here.

DISCUSSION

In order to assess the effects of IPPA and its designs on long-term functioning, neoplasia frequency in IPAA individuals, and IRA and IPAA outcomes in people with ulcerative colitis and concomitant PSC, the current clinical retrospective investigation was carried out. The study's findings demonstrated that none of the participants had high-grade dysplasia or cancer. Acute inflammation was observed to be present in 20.96% (n=39) and 24.73% (n=46) of the subjects, respectively, according to Examiners 1 and 2. Grade 3 was observed in 75.80% (n=141) and 51.07% (n=95) of the subjects, respectively, by Examiners 1 and 2, and Grade 4 in 79.03% (n=147) and 59.13% (n=110) of the subjects, respectively.

Examiner 2 observed Grades 1, 2, and 3 for chronic inflammation in 4.83% (n = 9) of the participants, whereas Examiners 1 and 2 saw Grades 25.80% (n = 48) and 23.11% (n = 43) and 53.76% (n = 100) and 73.11% (n = 136) of the subjects, respectively. Examiner 1 observed mucosal adaptation in 25.80% (n=48), 5.91% (n=11), and 58.06% (n=108) of the individuals, respectively, for Grades 1, 2, and 3. Grades 1, 2, and 3 were seen in 3.76% (n = 7), 18.81% (n = 35), and 48.92% (n = 91) of the patients in the ATZ region, respectively. These findings corroborated those of Anderson CA et al. (2011) and Fazio VW et al. (2013), who observed that individuals with UC or UC with PSC had comparable histopathologic features of mucosa and inflammation.

Subjects receiving IPAA therapy showed no difference between those with primary sclerosing cholangitis and ulcerative colitis alone. However, those with ulcerative colitis alone were more likely to receive a score of 8 or above. Individuals in the IRA group who also had primary sclerosing cholangitis and concomitant ulcerative colitis scored lower. 5.26% (n=2) of the individuals with UC and 28.57% (n=2) of the participants with UC with PSC had social impairment. In participants with UC, urgency was 42.85% (n=3) and 2.63% (n=1), respectively, with PSC. In 50% (n=19), 31.57% (n=12), and 13.15% (n=5) of the patients with UC, and in 0, 28.57% (n=2), and 57.14% (n=4) of the participants with UC with PSC, respectively, bowel movement occurred during the night.

In 28.94% (n=11), 50% (n=19), and 15.78% (n=6) of the patients with UC, and in 28.57% (n=2), 0, and 71.42% (n=5) of the participants with UC and PSC, respectively, bowel movement throughout the day was evaluated as 0, 1, and 2. These findings corroborated those of studies by Mizoguchi A et al. (2008) and Larsen S et al. (2010), which reported similar functional outcomes after ulcerative colitis therapy.

When it comes to issues and shortcomings, a greater proportion of participants with UC and PSC than those with UC alone experienced pouchitis. Pouchitis was observed early in UC with PSC individuals. Of the participants with UC and PSC, 12.5% (n=2) had pouchitis-related failure.

In 12.90% (n=4) of the participants with UC alone and 62.5% (n=10) of the subjects with UC plus PSC, there were more than four episodes of pouchitis. Of the subjects with pouchitis, 32.25% (n = 10) had UC by itself, and 81.25% (n = 13) had UC in conjunction with PSC. Within a year following surgery, the first episode of pouchitis was observed in 29.03% (n = 9) of participants with ulcerative colitis alone, and in 62.5% (n = 10) of subjects with UC and concomitant PSC. Proctitis did not significantly manifest in either UC-only or UC-plus-PSC individuals.

Failure rates were seen to be 15% and 5%, respectively, for participants treated with IPAA, UC with PSC, and UC alone. These results were statistically not significant. On the other hand, failure rates for participants receiving IRA treatment were 21% and 52% for UC alone and UC with PSC, respectively. There was statistical significance here. These outcomes were similar to those of trials conducted in 2010 by Joyce MR et al and in 2009 by Akbari RP et al, where the authors of both studies showed similar failure rates and consequences.

CONCLUSION

Within its limitations, the present study concludes that the best long-term functional outcomes were seen in K-pouch with stapled anastomosing in subjects with ulcerative colitis with a very low incidence of neoplasia following treatment. High failure rates and compromised functional outcomes are seen in subjects having UC and PSC treated with IRA. However, IPAA showed comparable outcomes in subjects having UC only or UC with PSC. The present study had a few limitations including a small sample size, shorter monitoring period, retrospective design, and geographical area biases. Hence, more longitudinal studies with a larger sample size and longer monitoring period will help reach a definitive conclusion.

REFERENCES

1. Loddo and C. Romano, “Inflammatory bowel disease: genetics, epigenetics, and pathogenesis,” *Frontiers in Immunology*. 2015;6:551.
2. Vancamelbeke, M., and Vermeire, S. The intestinal barrier: a fundamental role in health and disease. *Expert Rev. Gastroenterol. Hepatol.* 2017;11:821–34.
3. Cima RR, Pemberton JH. Medical and surgical management of chronic ulcerative colitis. *Arch Surg*. 2005;140:300–10.
4. Scoglio D, Ahmed Ali U, Fichera A. Surgical treatment of ulcerative colitis: ileorectal vs ileal pouch-anal anastomosis. *World J Gastroenterol.* 2014;20:13211–8.
5. Jeong SY, Moon JS, Park KJ, Kim YS. Successful treatment of postoperative fistula with infliximab in a patient with Crohn’s disease. Intest Res. 2014;12:74–7.
6. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet* 2011; 43:246-52.
7. Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch-anal anastomosis: analysis of outcome and quality of life in 3707 patients. *Annals of surgery* 2013;257:679-85.
8. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present, and future: lessons from animal models. *J Gastroenterol* 2008;43:1-17.
9. Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. *Ann Med* 2010;42:97-114.
10. Joyce MR, Kiran RP, Remzi FH, Church J, Fazio VW. In a select group of patients meeting strict clinical criteria and undergoing ileal pouch-anal anastomosis, the omission of a diverting ileostomy offers cost savings to the hospital. *Diseases of the colon and rectum* 2010;53:905-10.

11. Akbari RP, Madoff RD, Parker SC, et al. Anastomotic sinuses after ileoanal pouch construction: incidence, management, and outcome. *Diseases of the colon and rectum* 2009;52:452-5.

TABLES

Indefinite for Dysplasia (IFD)	Subgroups	Examiner 1 %(n)	Examiner 2 %(n)
The score for Acute Inflammation	Grade 0	0	0
	Grade 1	0	0
	Grade 2	20.96 (39)	24.73 (46)
	Grade 3	75.80 (141)	51.07 (95)
	Grade 4	79.03 (147)	59.13 (110)
	Grade 5	0	0
	Grade 6	0	0
The score forChronic Inflammation	Grade 1	0	4.83 (9)
	Grade 2	25.80 (48)	23.11 (43)
	Grade 3	53.76 (100)	73.11 (136)
Mucosal Adaptation	Grade 1	25.80 (48)	5.91 (11)
	Grade 2	5.91 (11)	23.11 (43)
	Grade 3	58.06 (108)	59.13 (110)
Chronic inflammation in ATZ	Grade 1	0	3.76 (7)
	Grade 2	16.12 (30)	18.81 (35)
	Grade 3	17.20 (32)	48.92 (91)

Table 1: IFD in pouch and grades of inflammation with chronic inflammation in ATZ in the study subjects

Parameter	Scores	Ulcerative colitis alone % (IRA n=38)	Ulcerative colitis with PSC % (IRA n=7)
Median score ≥8		7.89 (3)	28.57 (2) (NS)
Social Handicap	1	5.26 (2)	42.85 (3)
Urgency	1	2.63 (1)	42.85 (3)
Bowel movement during the night			
None	0	50 (19)	0 (NS)
1or less/week	1	31.57 (12)	28.57 (2) (NS)
2 or more/night	2	13.15 (5)	57.14 (4)
Bowel movement during daytime			
Less than/equal to 4	0	28.94 (11)	28.57 (2) (NS)
5	1	50 (19)	0 (NS)
More than/equal to 6	2	15.78 (6)	71.42 (5)

Table 2: Functional outcomes following IRA in the study subjects

Pouchitis Parameter	Ulcerative colitis alone % (IRA n=31)	Ulcerative colitis with PSC % (IRA n=16)
Failure owing to Pouchitis	0	12.5 (2)
1st episode within 1 year following treatment	29.03 (9)	62.5 (10)
Pouchitis time (years)	3.22 (1)	6.25 (1)
Pouchitis episodes	67.7 (21)	18.75 (3)
1-3 times	19.35 (6)	12.5 (2)
≥4 times	12.90 (4)	62.5 (10)
Subjects with pouchitis	32.25 (10)	81.25 (13)

Table 3: Pouchitis and associated clinicopathologic characteristics in the study subjects